CN110382522B - 血脑屏障穿过化合物及其用途 - Google Patents

血脑屏障穿过化合物及其用途 Download PDF

Info

Publication number
CN110382522B
CN110382522B CN201880015949.5A CN201880015949A CN110382522B CN 110382522 B CN110382522 B CN 110382522B CN 201880015949 A CN201880015949 A CN 201880015949A CN 110382522 B CN110382522 B CN 110382522B
Authority
CN
China
Prior art keywords
abp
seq
bbb
fragment
brain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880015949.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN110382522A (zh
Inventor
巴律·查克拉瓦蒂
D·斯坦尼米洛维克
Y·杜罗切尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Research Council of Canada
Original Assignee
National Research Council of Canada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Research Council of Canada filed Critical National Research Council of Canada
Publication of CN110382522A publication Critical patent/CN110382522A/zh
Application granted granted Critical
Publication of CN110382522B publication Critical patent/CN110382522B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201880015949.5A 2017-01-30 2018-01-30 血脑屏障穿过化合物及其用途 Active CN110382522B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762452015P 2017-01-30 2017-01-30
US62/452,015 2017-01-30
US201762530980P 2017-07-11 2017-07-11
US62/530,980 2017-07-11
PCT/IB2018/050576 WO2018138709A1 (en) 2017-01-30 2018-01-30 Blood-brain barrier transmigrating compounds and uses thereof

Publications (2)

Publication Number Publication Date
CN110382522A CN110382522A (zh) 2019-10-25
CN110382522B true CN110382522B (zh) 2024-08-30

Family

ID=62977950

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880015949.5A Active CN110382522B (zh) 2017-01-30 2018-01-30 血脑屏障穿过化合物及其用途
CN201880091218.9A Pending CN111886240A (zh) 2017-01-30 2018-07-31 血脑屏障迁移化合物及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201880091218.9A Pending CN111886240A (zh) 2017-01-30 2018-07-31 血脑屏障迁移化合物及其用途

Country Status (8)

Country Link
US (3) US11702466B2 (enExample)
EP (2) EP3574002A4 (enExample)
JP (4) JP7449092B2 (enExample)
KR (3) KR102676279B1 (enExample)
CN (2) CN110382522B (enExample)
AU (4) AU2018212860A1 (enExample)
CA (2) CA3052058A1 (enExample)
WO (2) WO2018138709A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102676279B1 (ko) * 2017-01-30 2024-06-20 내션얼 리서치 카운슬 오브 캐나다 혈액-뇌 장벽을 관통이동하는 화합물 및 이의 용도
JP7368856B2 (ja) 2017-07-25 2023-10-25 トゥルーバインディング，インコーポレイテッド Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療
CA3117409A1 (en) * 2018-10-29 2020-05-07 Biogen Ma Inc. Humanized and stabilized fc5 variants for enhancement of blood brain barrier transport
CN116063505B (zh) 2019-01-30 2024-05-03 真和制药有限公司 抗gal3抗体及其用途
EP4058479A4 (en) 2019-11-15 2024-02-28 University of Tennessee Research Foundation MODIFIED IMMUNOLOBULINES FOR TARGETING AMYLOID DEPOSITS
US12281166B2 (en) 2020-05-26 2025-04-22 Truebinding, Inc. Methods of treating inflammatory diseases by blocking Galectin-3
EP4333871A4 (en) * 2021-05-05 2025-05-07 University of Tennessee Research Foundation PEPTIDE-FC FUSIONS FOR THE TREATMENT OF AMYLOID DISEASES
CN117915949A (zh) * 2021-05-18 2024-04-19 田纳西大学研究基金会 用于治疗淀粉样蛋白病症的抗体-肽融合蛋白
KR102475326B1 (ko) * 2022-01-27 2022-12-07 한국기초과학지원연구원 신규한 펩타이드 유사체 및 이를 포함하는 알츠하이머 병 예방 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006133566A1 (en) * 2005-06-17 2006-12-21 National Research Council Of Canada NOVEL Aß-BINDING PROTEIN AND ITS PEPTIDE DERIVATIVES AND USES THEREOF

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5385915A (en) 1990-05-16 1995-01-31 The Rockefeller University Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation
EP0711303B2 (en) 1993-07-30 2009-06-10 Affymax, Inc. Biotinylation of proteins
AU2001263006A1 (en) 2000-05-18 2001-11-26 Hyseq, Inc. Novel nucleic acids and polypeptides
EP1328626B1 (en) * 2000-05-26 2013-04-17 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
AU2001268855A1 (en) * 2000-05-26 2001-12-03 National Research Council Of Canada Single-domain antigen-binding antibody fragments derived from llama antibodies
AU2002304814A1 (en) 2001-03-14 2002-11-05 Hybrigenics Protein-protein interactions in adipocytes
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
JP2003135075A (ja) * 2001-11-05 2003-05-13 Research Association For Biotechnology 新規な全長ｃＤＮＡ
ATE394673T1 (de) 2001-11-30 2008-05-15 Ca Nat Research Council Selbstanordnende moleküle
EP1452601A1 (en) 2003-02-28 2004-09-01 Roche Diagnostics GmbH Enhanced expression of fusion polypeptides with a biotinylation tag
EP2214018B1 (en) * 2004-04-27 2013-06-26 Galapagos N.V. Methods, agents, and compound screening assays for inducing differentiation of undifferentiated mammalian cells into osteoblasts
CA2623841C (en) 2005-09-27 2019-03-12 National Research Council Of Canada Methods of identifying agents capable of tmem30a mediated transmigration across the blood brain barrier (bbb)
TW200907056A (en) * 2007-03-28 2009-02-16 Astrazeneca Ab New method
US8986689B2 (en) 2010-04-14 2015-03-24 National Research Council Of Canada Compositions and methods for brain delivery of analgesic peptides
US20110269735A1 (en) * 2010-04-19 2011-11-03 Celera Corporation Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof
US9066986B2 (en) 2010-10-01 2015-06-30 National Research Council Of Canada Anti-CEACAM6 antibodies and uses thereof
WO2013106577A2 (en) 2012-01-10 2013-07-18 Biogen Idec Ma Inc. Enhancement of transport of therapeutic molecules across the blood brain barrier
PT2890712T (pt) 2012-08-29 2019-06-28 Hoffmann La Roche Transportador para a barreira hematoencefálica
US10112998B2 (en) * 2014-03-06 2018-10-30 National Research Council Of Canada Insulin-like growth factor 1 receptor-specific antibodies and uses thereof
DK3114140T3 (da) * 2014-03-06 2019-06-03 Nat Res Council Canada Insulinlignende vækstfaktor 1-receptorspecifikke antistoffer og anvendelser deraf
NZ724866A (en) 2014-03-06 2022-04-29 Nat Res Council Canada Insulin-like growth factor 1 receptor -specific antibodies and uses thereof
ES2924282T3 (es) * 2014-12-19 2022-10-05 Medimmune Ltd Moléculas de transporte a través de la barrera hematoencefálica y usos de las mismas
ES3028883T3 (en) * 2015-08-31 2025-06-20 Nat Res Council Canada Tgf-beta-receptor ectodomain fusion molecules and uses thereof
MX389765B (es) 2016-07-06 2025-03-20 Nat Res Council Canada Anticuerpos humanizados que transmigran a traves de la barrera hematoencefalica y usos de los mismos.
EP3551666A4 (en) 2016-12-12 2020-07-29 National Research Council of Canada VARIANTS OF ANTIBODIES CROSSING THE HEMATOENCEPHALIC BARRIER AND THEIR USES
KR102676279B1 (ko) 2017-01-30 2024-06-20 내션얼 리서치 카운슬 오브 캐나다 혈액-뇌 장벽을 관통이동하는 화합물 및 이의 용도

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006133566A1 (en) * 2005-06-17 2006-12-21 National Research Council Of Canada NOVEL Aß-BINDING PROTEIN AND ITS PEPTIDE DERIVATIVES AND USES THEREOF

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
A novel platform for engineering blood-brain barrier- crossing bispecific biologics;Graham K. Farrington等;《FASEB Journal》;20141130;第4764-4778页 *

Also Published As

Publication number Publication date
KR20240095466A (ko) 2024-06-25
JP2023123535A (ja) 2023-09-05
AU2018405992A1 (en) 2020-08-20
JP7449092B2 (ja) 2024-03-13
JP2024081644A (ja) 2024-06-18
CA3089816A1 (en) 2019-08-08
KR20200116143A (ko) 2020-10-08
EP3574002A1 (en) 2019-12-04
KR20190112768A (ko) 2019-10-07
JP2021512159A (ja) 2021-05-13
KR102676279B1 (ko) 2024-06-20
AU2022202015A1 (en) 2022-04-14
CN110382522A (zh) 2019-10-25
AU2024201813A1 (en) 2024-04-11
EP3746460A1 (en) 2020-12-09
CA3052058A1 (en) 2018-08-02
AU2018212860A1 (en) 2019-08-15
JP7458327B2 (ja) 2024-03-29
US20190352383A1 (en) 2019-11-21
US20230257424A1 (en) 2023-08-17
WO2018138709A1 (en) 2018-08-02
US20230279088A1 (en) 2023-09-07
EP3574002A4 (en) 2021-04-21
US11702466B2 (en) 2023-07-18
WO2019150183A1 (en) 2019-08-08
EP3746460A4 (en) 2022-04-20
CN111886240A (zh) 2020-11-03
AU2022202015B2 (en) 2023-12-21
JP2020505926A (ja) 2020-02-27

Similar Documents

Publication Publication Date Title
CN110382522B (zh) 血脑屏障穿过化合物及其用途
AU2022252753B2 (en) ANTIBODIES TO a-SYNUCLEIN AND USES THEREOF
CN102459333B (zh) 抗-Tau pS422抗体用于治疗脑病的应用
AU2018312441B2 (en) Antibody binding active alpha-synuclein
EA035480B1 (ru) Антитела, специфические к рецептору инсулиноподобного фактора роста 1 и их применения
EA035517B1 (ru) Антитела, специфические к рецептору инсулиноподобного фактора роста 1, и их применения
JP7254931B2 (ja) 抗アルファ－シヌクレイン抗体およびその使用
HK40022840B (zh) 抗α-突触核蛋白抗体及其用途
HK1166331B (en) Use of an anti-tau ps422 antibody for the treatment of brain diseases
HK1234078B (zh) 新的抗人tie-2抗体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant